Medivation (MDVN) Preclinical Excitement Seems To Be Bearing Fruit - Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
AstraZeneca (AZN) Considering Offer for Medivation (MDVN) - Times
April 18, 2016 7:14 AM EDTAstraZeneca (NYSE: AZN) has held internal talks and is looking very closely at an offer for Medivation (NASDAQ: MDVN), according to The Times.
Medivation (MDVN) Taps Session High
April 15, 2016 9:55 AM EDTMedivation (NASDAQ: MDVN) advanced Friday morning, rising 6%.
Leerink Highlights Top 10 Biopharma Stocks for Partnerships & Acquisitions
April 14, 2016 12:07 PM EDTIn addition to naming Acadia Pharma (NASDAQ: ACAD) one of his top partnership and acquisition (P&A) targets, as noted earlier, Leerink analyst Joseph Schwartz listed 9 other stocks on his Top 10 list. Below is a run-down of the others:
Akorn, Inc. (NASDAQ: AKRX) (Market Perform)
Rationale for P&A: "AKRX operates in generic segments with higher barriers... More
